Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이진화 | * |
dc.date.accessioned | 2016-08-28T12:08:02Z | - |
dc.date.available | 2016-08-28T12:08:02Z | - |
dc.date.issued | 2010 | * |
dc.identifier.issn | 0954-6111 | * |
dc.identifier.other | OAK-6438 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/220676 | - |
dc.description.abstract | Rationale: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disorder in which a number of different pathological processes lead to recognition of patient subgroups that may have individual characteristics and distinct responses to treatment. Objectives: We tested the hypothesis that responses of lung function to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid might differ among patients with various COPD subtypes. Methods: We classified 165 COPD patients into four subtypes according to the severity of emphysema and airflow obstruction: emphysema-dominant, obstruction-dominant, mild-mixed, and severe-mixed. The emphysema-dominant subtype was defined by an emphysema index on computed tomography of more than 20% and FEV1 more than 45% of the predicted value. The obstruction-dominant subtype had an emphysema index ≤ 20% and FEV1 ≤ 45%, the mild-mixed subtype had an emphysema index ≤ 20% and FEV1 > 45%, and the severe-mixed subtype had an emphysema index > 20% and FEV1 ≤ 45%. Patients were recruited prospectively and treated with 3 months of combined inhalation of long-acting beta-agonist and corticosteroid. Results: After 3 months of combined inhalation of long-acting beta-agonist and corticosteroid, obstruction-dominant subtype patients showed a greater FEV1 increase and more marked dyspnea improvement than did the emphysema-dominant subgroup. The mixed-subtype patients (both subgroups) also showed significant improvement in FEV1 compared with the emphysema-dominant subgroup. Emphysema-dominant subtype patients showed no improvement in FEV1 or dyspnea after the 3-month treatment period. Conclusion: The responses to 3 months of combined inhalation of long-acting beta-agonist and corticosteroid differed according to COPD subtype. © 2009 Elsevier Ltd. All rights reserved. | * |
dc.language | English | * |
dc.title | Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 104 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 542 | * |
dc.relation.lastpage | 549 | * |
dc.relation.journaltitle | Respiratory Medicine | * |
dc.identifier.doi | 10.1016/j.rmed.2009.10.024 | * |
dc.identifier.wosid | WOS:000276498700009 | * |
dc.identifier.scopusid | 2-s2.0-77649179376 | * |
dc.author.google | Lee J.-H. | * |
dc.author.google | Lee Y.K. | * |
dc.author.google | Kim E.-K. | * |
dc.author.google | Kim T.-H. | * |
dc.author.google | Huh J.W. | * |
dc.author.google | Kim W.J. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Lee S.-M. | * |
dc.author.google | Lee S. | * |
dc.author.google | Lim S.Y. | * |
dc.author.google | Shin T.R. | * |
dc.author.google | Yoon H.I. | * |
dc.author.google | Sheen S.S. | * |
dc.author.google | Kim N. | * |
dc.author.google | Seo J.B. | * |
dc.author.google | Oh Y.-M. | * |
dc.author.google | Lee S.D. | * |
dc.contributor.scopusid | 이진화(56646645800;58376333800) | * |
dc.date.modifydate | 20240419140935 | * |